Coherus Biosciences announces FDA acceptance of 351(K) biologics license application to U.S. FDA for CHS-1701 (pegfilgrastim biosimilar candidate)

6 October 2016 - Coherus BioSciences today announced that the U.S. FDA has accepted the filing of 351(k) biologics license application for CHS-1701, a pegfilgrastim (Neulasta) biosimilar candidate.

The submission is supported by similarity data from analytical, pharmacokinetic, pharmacodynamic and immunogenicity studies comparing CHS-1701 and Neulasta. The biosimilar user fee act (BSUFA) action date is 9 June  2017. 

Read Coherus Biosciences press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Submission